Marksans Pharma Latest Update

Recent Approvals and Business Developments : UK Regulatory Approval for Sennosides Tablets: Marksans Pharma's UK-based subsidiary, Relonchem Ltd, received marketing authorization from the UK MHRA for Sennosides 7.5 mg tablets, used to treat constipation. This news, reported on May 19, 2025, led to a significant jump in Marksans Pharma's share price. UK Regulatory Approval for Gabapentin Oral Solution: Just a week prior, Relonchem Ltd also secured UKMHRA approval for Gabapentin Oral Solution (50 mg/ml), used for epilepsy and nerve pain. Strong Financial Performance: Marksans Pharma reported its financial results for the quarter ending March 2025, showing net sales of Rs 708.46 crore (the highest in five quarters) and a Profit After Tax (PAT) of Rs 195.11 crore for the past six months, reflecting a 20.79% year-on-year growth. Board Meeting and Dividend Consideration: A board meeting was scheduled for May 19, 2025, to consider and approve the audited financial results for the quarter and year ended March 31, 2025, and to consider recommending a dividend for FY 2024-25. Appointment of New Director: The Board approved the appointment of Mr. Srinivas Mishra as an additional non-executive and Independent Director. USFDA Approvals: Marksans Pharma has received USFDA approvals for various products, including Guaifenesin Extended-Release Tablets (OTC) and Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC). They also received final approval for Acetaminophen and Ibuprofen Tablets (OTC). Successful Inspections: The company's manufacturing facility in Goa and its US subsidiary, Time-Cap Laboratories, Inc., have successfully undergone inspections from German health authorities and the USFDA, respectively, with no 483's issued during the audits. Acquisition: Marksans Pharma completed the acquisition of a manufacturing site from Tevapharm India in Goa.